keyword
MENU ▼
Read by QxMD icon Read
search

Antidepressant augmentation

keyword
https://www.readbyqxmd.com/read/28718661/anxiety-and-self-care-behaviour-in-patients-with-chronic-systolic-heart-failure-a-multivariate-model
#1
Thomas Müller-Tasch, Bernd Löwe, Nicole Lossnitzer, Lutz Frankenstein, Tobias Täger, Markus Haass, Hugo Katus, Jobst-Hendrik Schultz, Wolfgang Herzog
BACKGROUND: While comprehensive evidence exists regarding negative effects of depression on self-care behaviours in patients with chronic heart failure (CHF), the relation between anxiety and self-care behaviours in patients with CHF is not clear. The aim of this study was to analyse the interactions between anxiety, depression and self-care behaviours in patients with CHF. METHODS: The self-care behaviour of CHF outpatients was measured using the European Heart Failure Self-care Behaviour Scale (EHFScBS)...
July 1, 2017: European Journal of Cardiovascular Nursing
https://www.readbyqxmd.com/read/28697253/effect-of-antidepressant-switching-vs-augmentation-on-remission-among-patients-with-major-depressive-disorder-unresponsive-to-antidepressant-treatment-the-vast-d-randomized-clinical-trial
#2
Somaia Mohamed, Gary R Johnson, Peijun Chen, Paul B Hicks, Lori L Davis, Jean Yoon, Theresa C Gleason, Julia E Vertrees, Kimberly Weingart, Ilanit Tal, Alexandra Scrymgeour, David D Lawrence, Beata Planeta, Michael E Thase, Grant D Huang, Sidney Zisook, Sanjai D Rao, Patricia D Pilkinton, James A Wilcox, Ali Iranmanesh, Mamta Sapra, George Jurjus, James P Michalets, Muhammed Aslam, Thomas Beresford, Keith D Anderson, Ronald Fernando, Sriram Ramaswamy, John Kasckow, Joseph Westermeyer, Gihyun Yoon, D Cyril D'Souza, Gunnar Larson, William G Anderson, Mary Klatt, Ayman Fareed, Shabnam I Thompson, Carlos J Carrera, Solomon S Williams, Timothy M Juergens, Lawrence J Albers, Clifford S Nasdahl, Gerardo Villarreal, Julia L Winston, Cristobal A Nogues, K Ryan Connolly, Andre Tapp, Kari A Jones, Gauri Khatkhate, Sheetal Marri, Trisha Suppes, Joseph LaMotte, Robin Hurley, Aimee R Mayeda, Alexander B Niculescu, Bernard A Fischer, David J Loreck, Nicholas Rosenlicht, Steven Lieske, Mitchell S Finkel, John T Little
Importance: Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant. Objective: To determine the relative effectiveness and safety of 3 common alternate treatments for MDD. Design, Setting, and Participants: From December 2012 to May 2015, 1522 patients at 35 US Veterans Health Administration medical centers who were diagnosed with nonpsychotic MDD, unresponsive to at least 1 antidepressant course meeting minimal standards for treatment dose and duration, participated in the study...
July 11, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28687505/xiaochaihutang-attenuates-depressive-anxiety-like-behaviors-of-social-isolation-reared-mice-by-regulating-monoaminergic-system-neurogenesis-and-bdnf-expression
#3
Jie Ma, Fang Wang, Jingyu Yang, Yingxu Dong, Guangyue Su, Kuo Zhang, Xing Pan, Ping Ma, Tingshuo Zhou, Chunfu Wu
ETHNOPHARMACOLOGICAL RELEVANCE: Xiaochaihutang (XCHT), as a classical herbal formula for the treatment of "Shaoyang syndrome" has been demonstrated to exert an antidepressant effect in multiple animal models of depression as shown in our previous studies. However, the effects of XCHT on social isolation (SI)-reared mice have not been investigated. This study aims to explore the effects of XCHT on depressive/anxiety-like behaviors of SI-reared mice, and its implicated mechanisms, including alterations in the monoaminergic system, neurogenesis and neurotrophin expression...
July 5, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28682528/s-adenosylmethionine-same-for-neuropsychiatric-disorders-a-clinician-oriented-review-of-research
#4
REVIEW
Anup Sharma, Patricia Gerbarg, Teodoro Bottiglieri, Lila Massoumi, Linda L Carpenter, Helen Lavretsky, Philip R Muskin, Richard P Brown, David Mischoulon
OBJECTIVE: A systematic review on S-adenosylmethionine (SAMe) for treatment of neuropsychiatric conditions and comorbid medical conditions. DATA SOURCES: Searches were conducted in PubMed, EMBASE, PsycINFO, Cochrane Library, CINAHL, and Google Scholar databases between July 15, 2015, and September 28, 2016, by combining search terms for SAMe (s-adenosyl methionine or s-adenosyl-l-methionine) with terms for relevant disease states (major depressive disorder, MDD, depression, perinatal depression, human immunodeficiency virus, HIV, Parkinson's, Alzheimer's, dementia, anxiety, schizophrenia, psychotic, 22q11...
June 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28677866/increased-incidence-of-non-alcoholic-fatty-liver-disease-in-male-rat-offspring-exposed-to-fluoxetine-during-fetal-and-neonatal-life-involves-the-nlrp3-inflammasome-and-augmented-de-novo-hepatic-lipogenesis
#5
Nicole E De Long, Daniel B Hardy, Noelle Ma, Alison C Holloway
Up to 10% of women take selective serotonin reuptake inhibitors (SSRI) during pregnancy. Children exposed to SSRIs in utero have an increased risk of being overweight suggesting that fetal exposure to SSRIs can cause permanent metabolic changes. We have previously shown in rats that fetal and neonatal exposure to the SSRI antidepressant fluoxetine results in metabolic perturbations including increased hepatic triglyceride content; a hallmark of non-alcoholic fatty liver disease (NAFLD). Therefore, the aim of this study was to identify the mechanism(s) underlying the fluoxetine-induced increase in intrahepatic triglyceride content...
July 5, 2017: Journal of Applied Toxicology: JAT
https://www.readbyqxmd.com/read/28651526/study-protocol-for-a-randomised-pragmatic-trial-comparing-the-clinical-and-cost-effectiveness-of-lithium-and-quetiapine-augmentation-in-treatment-resistant-depression-the-lqd-study
#6
L Marwood, R Taylor, K Goldsmith, R Romeo, R Holland, A Pickles, J Hutchinson, D Dietch, A Cipriani, R Nair, M-J Attenburrow, A H Young, J Geddes, R H McAllister-Williams, A J Cleare
BACKGROUND: Approximately 30-50% of patients with major depressive disorder can be classed as treatment resistant, widely defined as a failure to respond to two or more adequate trials of antidepressants in the current episode. Treatment resistant depression is associated with a poorer prognosis and higher mortality rates. One treatment option is to augment an existing antidepressant with a second agent. Lithium and the atypical antipsychotic quetiapine are two such add-on therapies and are currently recommended as first line options for treatment resistant depression...
June 26, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28645191/how-effective-is-algorithm-guided-treatment-for-depressed-inpatients-results-from-the-randomized-controlled-multicenter-german-algorithm-project-3-trial
#7
Mazda Adli, Katja Wiethoff, Thomas C Baghai, Robert Fisher, Florian Seemüller, Gregor Laakmann, Peter Brieger, Joachim Cordes, Jaroslav Malevani, Gerd Laux, Iris Hauth, Hans-Jürgen Möller, Klaus-Thomas Kronmüller, Michael N Smolka, Peter Schlattmann, Maximilian Berger, Roland Ricken, Thomas J Stamm, Andreas Heinz, Michael Bauer
Background: Treatment algorithms are are considered as key to improve outcomes by enhancing the quality of care. This is the first randomized controlled study to evalutate the clinical effect of algorithm-guided treatment in inpatients with major depressive disorder (MDD). Methods: Inpatients, aged 18-70 years with MDD from 10 German psychiatric departments were randomized to 5 different treatment arms (from 2000 to 2005), three of which were standardized stepwise drug treatment algorithms (ALGO)...
June 22, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28629442/treatment-patterns-healthcare-resource-utilization-and-costs-following-first-line-antidepressant-treatment-in-major-depressive-disorder-a-retrospective-us-claims-database-analysis
#8
Geneviève Gauthier, Annie Guérin, Maryia Zhdanava, William Jacobson, George Nomikos, Elizabeth Merikle, Clément François, Vanessa Perez
BACKGROUND: Although the symptoms of major depressive disorder (MDD) are often manageable with pharmacotherapy, response to first-line antidepressant treatment is often less than optimal. This study describes long-term treatment patterns in MDD patients in the United States and quantifies the economic burden associated with different treatment patterns following first-line antidepressant therapy. METHODS: MDD patients starting first-line antidepressant monotherapy and having continuous enrollment ≥12 months before and ≥24 months following the index date (i...
June 19, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28617392/-panic-disorder-clinical-phenomena-and-treatment-options
#9
Yu P Sivolap
Panic disorder is a common mental disease with high psychiatric comorbidity. It is considered that a combination of genetic predisposition and a special psychic vulnerability plays a key role in the occurrence of panic disorder. Clinically proven efficacy in the treatment of panic disorder have benzodiazepines, tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors; antidepressants from other pharmaceutical groups are also used...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28601279/escitalopram-or-novel-herbal-treatments-differentially-alter-cytokine-and-behavioral-responses-to-immune-challenge
#10
Ronit Avitsur, Shalva Paley, Motty Franko, Nizan Wolff, Nir Eyal, Ravid Doron
Studies suggest that inflammation is involved in the pathophysiology of depression. The present study examined the effects of the commonly used antidepressant escitalopram, in comparison with a novel herbal treatment (NHT) consisted of Crataegus pinnatifida, Triticum aestivum, Lilium brownii and Fructus Ziziphus jujuba, on cytokine and behavioral responses to an immune challenge. Escitalopram augmented lipopolysaccharide-induced tumor necrosis factor (TNF)-α peripheral secretion and induced a faster kinetics of interleukin-1β secretion, while marginally reducing sickness behavior...
August 15, 2017: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/28597528/enhancement-of-recovery-from-mental-illness-with-l-methylfolate-supplementation
#11
REVIEW
Gerald Martone
People suffering from depression, schizophrenia, and dementia often have measurably lower levels of serum folate compared to people not experiencing psychiatric disorders. Augmentation of SSRI and SNRI antidepressant medications with l-methylfolate has been demonstrated to increase their effectiveness and onset of action. Even the use of l-methylfolate as a stand-alone monotherapy has been observed to exert antidepressant properties. The role of folate in mental illness has been known for many decades, but the strategic use of l-methylfolate supplementation has not yet been accepted as a standard regimen...
June 8, 2017: Perspectives in Psychiatric Care
https://www.readbyqxmd.com/read/28591669/bupropion-induces-social-anxiety-in-adolescent-mice-influence-of-housing-conditions
#12
Carmen Gómez, Rosa Redolat, Carmen Carrasco
BACKGROUND: The antidepressant bupropion has received increasing attention as a pharmacological tool to treat addiction although little is known about its effects on social behaviour in adolescents. The present study aimed to evaluate if environmental housing conditions influence bupropion's actions on social behaviour of adolescent mice. METHODS: Mice were either group- or individually housed for 2-weeks and then randomly divided into 2 cohorts: half of the mice remained in the initial housing condition and the other half were changed to isolated conditions for further 2-weeks...
March 22, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28584694/liothyronine-for-depression-a-review-and-guidance-for-safety-monitoring
#13
REVIEW
Katie T B Touma, Allysa M Zoucha, Jonathan R Scarff
Objective: The objective of this review is to discuss triiodothyronine's (T3, liothyronine) mechanism of action, efficacy in enhancement and augmentation trials, and dosing and safety considerations for the treatment of depression. Method: A literature search of PubMed was performed using search terms depression, augmentation, antidepressant, and liothyronine. Only English-language studies of subjects with unipolar depression were included from the past 50 years. Results: Most studies have shown that liothyronine is an efficacious enhancement and augmentation strategy for depression in combination with antidepressants, primarily tricyclic antidepressants and selective serotonin reuptake inhibitors...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28582570/phase-ii-proof-of-concept-trial-of-the-orexin-receptor-antagonist-filorexant-mk-6096-in-patients-with-major-depressive-disorder
#14
Kathryn M Connor, Paulette Ceesay, Jill Hutzlemann, Duane Snavely, Andrew D Krystal, Madhukar H Trivedi, Michael Thase, Christopher Lines, W Joseph Herring, David Michelson
Background: We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with major depressive disorder (MDD). Methods: Six-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept study. Patients with MDD (partial responders to ongoing antidepressant therapy) were randomized 1:1 to once-daily oral filorexant 10mg or matching placebo. Results: Due to enrollment challenges the study was terminated early, resulting in insufficient statistical power to detect a pre-specified treatment difference; of 326 patients planned, 129 (40%) were randomized and 128 took treatment...
June 3, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28545010/factors-associated-with-response-after-deep-transcranial-magnetic-stimulation-in-a-real-world-clinical-setting-results-from-the-first-40-cases-of-treatment-resistant-depression
#15
K Feffer, K A B Lapidus, Y Braw, Y Bloch, S Kron, R Netzer, U Nitzan
BACKGROUND: Deep transcranial magnetic stimulation (dTMS) has been sanctioned by the United States Food and Drug Administration for treatment-resistant depression. In a retrospective cohort study, we evaluated response and effectiveness of dTMS in real-world practice, as an add-on treatment for resistant depression. METHODS: Forty adult outpatients suffering from depression, all taking psychiatric medications, underwent 20 dTMS treatments over a 4-6 week period...
April 11, 2017: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/28537967/nortriptyline-enhances-morphine-conditioned-place-preference-in-neuropathic-rats-role-of-the-central-noradrenergic-system
#16
Wenli Mi, Shuxing Wang, Zerong You, Grewo Lim, Michael F McCabe, Hyangin Kim, Lucy Chen, Jianren Mao
BACKGROUND: Combination drug therapy is commonly used to treat chronic pain conditions such as neuropathic pain, and antidepressant is often used together with opioid analgesics. While rewarding is an intrinsic property of opioid analgesics, it is unknown whether the use of an antidepressant would influence opioid reward, which may contribute to opioid addiction. In this study, we examined whether nortriptyline (a tricyclic antidepressant and a first-line medication for neuropathic pain) would enhance the morphine rewarding property in both naive and chronic constriction sciatic nerve injury (CCI) rats...
May 19, 2017: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/28505669/add-on-antidepressants-in-the-naturalistic-treatment-of-schizophrenia-spectrum-disorder-when-who-and-how
#17
Rebecca Schennach, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G Schmidt, Wolfgang Gaebel, Joachim Klosterkötter, Isabella Heuser, Wolfgang Maier, Matthias R Lemke, Eckart Rüther, Stefan Klingberg, Markus Gastpar, Ilja Spellmann, Richard Musil, Hans-Jürgen Möller, Michael Riedel
The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/without antidepressant add-on were compared regarding clinical and treatment-related variables, response and remission, and remission of depressive and negative symptoms. The efficacy of antidepressant add-on treatment was furthermore analyzed applying marginal structure models...
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28484990/behavioral-and-biochemical-impact-of-chronic-unpredictable-mild-stress-on-the-acquisition-of-nicotine-conditioned-place-preference-in-rats
#18
G Biala, K Pekala, A Boguszewska-Czubara, A Michalak, M Kruk-Slomka, K Grot, B Budzynska
Addiction is a chronic psychiatric disease which represents a global problem, and stress can increase drug addiction and relapse. Taking into account frequent concomitance of nicotine dependence and stress, the purpose of the present study was to assess behavioral and biochemical effects of chronic unpredictable mild stress (CUMS) exposure on nicotine reward in rats measured in the conditioned place preference (CPP) paradigm. Rats were submitted to the CUMS for 3 weeks and conditioned with nicotine (0.175 mg/kg) for 2 or 3 days...
May 8, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28441583/randomized-controlled-trial-of-repetitive-transcranial-magnetic-stimulation-combined-with-paroxetine-for-the-treatment-of-patients-with-first-episode-major-depressive-disorder
#19
Yu-Mei Wang, Ning Li, Lin-Lin Yang, Mei Song, Le Shi, Wen-Hao Chen, Su-Xia Li, Xue-Yi Wang, Lin Lu
Repetitive transcranial magnetic stimulation (rTMS) has been introduced as a new and effective treatment option for major depression. This paper examined the effectiveness of rTMS on first episode depressed patients when combined with antidepressant drugs. A random sample of forty-three first-episode depressed patients received active or sham rTMS to the left dorsolateral prefrontal cortex, and concomitantly took paroxetine for 4 weeks, and paroxetine monotherapy for 4 weeks afterwards. Response was defined as a ≥50% decrease on the total Hamilton Depression Rating Scale (HDRS) from the baseline, and remission was defined as an HDRS total residual score <8...
April 8, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28436756/the-role-of-attachment-style-in-interpersonal-psychotherapy-for-depressed-adolescents
#20
Meredith Gunlicks-Stoessel, Ana Westervelt, Kristina Reigstad, Laura Mufson, Susanne Lee
OBJECTIVE(S): This study examined changes in depressed adolescents' reports of attachment anxiety and avoidance with interpersonal psychotherapy (IPT-A), and the relationship between attachment style and change in depression with IPT-A. METHOD: Forty adolescents (aged 12-17) participated in a 16-week randomized clinical trial of 4 adaptive treatment strategies for adolescent depression that began with IPT-A and augmented treatment for insufficient responders (n = 22) by adding additional IPT-A sessions (n = 11) or the antidepressant medication, fluoxetine (n = 11)...
April 24, 2017: Psychotherapy Research: Journal of the Society for Psychotherapy Research
keyword
keyword
86292
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"